Similarly, in the PFS analysis, two original studies (Owonikoko et al., 2019; Ai et al., 2021) suggested that PARP inhibitor-containing regimens could prolong the PFS of lung cancer patients. This evidence concerns the gene PARP1 and lung cancer.